All of them employ ULD of SNA-MYC to target the product of the proto-oncogene cellular myelocytomatosis (c-myc), an oncoprotein involved in the development and progression of a wide range of cancers, including CRC, prostate cancer (PC), and breast cancer (BC) [8,9,10,11,12,13,14,15]. Here, MYC is linked to pachyonychia congenita.